Irinotecan Hydrochloide

Irinotecan hydrochloride injection is indicated as a component of first-line therapy in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic carcinoma of the colon or rectum. Irinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. Irinotecan hydrochloride injection is a topoisomerase inhibitor indicated for: ; First-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum.

12.1 Mechanism of Action Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I, which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38.

Clinical clearance of Irinotecan Hydrochloide (Topoisomerase Inhibitor) relies on primary cyp3a4 cytochrome processing paired with glucuronide elimination for irinotecan hydrochloide with a 6 to 12 hours terminal elimination (Irinotecan Hydrochloide SPL) half-life; patients absorbing at Complete (~100%) parenteral systemic delivery for Irinotecan Hydrochloide (20 mg/mL Injection) bioavailability typically observe target onset around rapid intravascular/parenteral onset within 15–45 minutes after irinotecan hydrochloide administration.

FDA clinical labeling for Irinotecan Hydrochloide restricts administration in 4 contraindications; irinotecan hydrochloride injection is contraindicated in patients with a known hypersensitivity to the drug or its excipients.; hypersensitivity to irinotecan hydrochloride injection or its excipients (4) across 20 mg/mL Injection, 125 mg, 20 mg, with self-reported patient tracking dominated by nausea (11% of reports), diarrhea (8.3% of reports), constipation (5.5% of reports).